• Moxifloxacin hydrochloride packaged and labeled.

click on thumbnail to zoom
SKU: M033

  Click 'Bulk Order' for 10 or more
Price: make selection(s)

Moxifloxacin Hydrochloride is a broad-spectrum fourth-generation fluoroquinolone antibiotic that can be used against the bacteria causing respiratory infections. Moxifloxacin Hydrochloride is sparingly soluble in aqueous solution.

    CAS Number


    Molecular Formula

    C21H24FN3O4 · HCl

    Molecular Weight


    Mechanism of Action

    Fluoroquinolone antibiotics target bacterial DNA gyrase, an enzyme which reduces DNA strain during replication. Because DNA gyrase is required during DNA replication, subsequent DNA synthesis and ultimately cell division is inhibited.

    Moxifloxacin is bactericidal against wild-type and first-step gyrase- and topoisomerase IV-resistant mutants.  The 8-methoxy group on moxifloxacin appeared to significantly lower the propensity for quinolone resistance development (Dalhoff, 2011).

    Storage Conditions


    Tariff Code



    Moxifloxacin is a broad-spectrum antibiotic commonly used Gram-positive and Gram-negative bacteria. It is effective against bacteria that case respiratory infections including S. pneumonia. It is also effective for obligate anaerobes including Bacteriodes, Fusobacterium, Bilophila, and Clostridium.


    Eukaryotic Cell Culture Applications

    A cell culture model to investigate the safety of moxifloxacin for intracameral application was investigated in cultured human corneas to review endothelial toxicity.  Moxifloxacin at 10-750 ug/ml was evaluated in endothelial cells, primary human trabecular meshwork cells (TMC), and primary human retinal pigment epithelial (RPE) cells.  Concentrations up to 150 ug/ml had no influence on endothelial cells, TMC, or RPE when exposed for up to 24 hours (MIC90 is 0.25-2.5 ug/ml).(Kernt et al, 2009).

    Microbiology Applications

    Moxifloxacin Hydrochloride is commonly used in clinical in vitromicrobiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-positive and Gram-negative microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options for infected patients. Representative MIC values include:

    • Haemophilus influenzae 0.008 µg/mL – 0.25 µg/mL
    • Streptococcus pneumoniae 0.03 µg/mL - 8 µg/mL
    • For a complete list of moxifloxacin values, click here.





    Yellow powder



    Impurity Profile

    Impurity A| 1-Cyclopropyl-6,8-difluoro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; Moxifloxacin Difluoro Analog|151213-15-9|C20H21F2N3O3|389.40| Impurity B| 1-Cyclopropyl-6,8-dimethoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; Moxifloxacin Dimethoxy Analog||C22H27N3O5|413.47| Impurity C| 1-Cyclopropyl-8-ethoxy-6-fluoro-7-[(4aS,7aS)-octahydro-6H-pyrrolo [3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; Moxifloxacin Ethyl Analog||C22H26FN3O4|415.46| Impurity D| 1-Cyclopropyl-8-fluoro-6-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo [3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; Moxifloxacin Isomer|1029364-77-9|C21H24FN3O4|401.43| Impurity E| 1-Cyclopropyl-6-fluoro-8-hydroxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo [3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; Moxifloxacin Desmethyl Analog||C20H22FN3O4|387.4| Moxifloxacin Decarboxy Analog| Decarboxy Moxifloxacin;1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline||C20H24FN3O2|357.42| Moxifloxacin Difluoro Hydroxy Impurity| 1-Cyclopropyl-6,7-difluoro-1,4-dihydro-8-hydroxy-4-oxo-3-quinoline carboxylic acid|154093-72-8|C13H9F2NO4|281.21| Moxifloxacin Difluoro Methoxy Impurity| 1-Cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline carboxylic acid|112811-72-0|C14H11F2NO4|295.24| Moxifloxacin N-Methyl Analog| 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-1-methyl-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid hydrochloride||C22H27ClFN3O4|451.92| Moxifloxacin Trifluoro Ethyl Ester| 1-Cyclopropyl-6,7,8-trifluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid ethyl ester|94242-51-0|C15H12F3NO3|311.26| Moxifloxacin Trifluoro Impurity| 1-Cyclopropyl-6,7,8-trifluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid|94695-52-0|C13H8F3NO3|283.20| Moxifloxacin Methyl Ester| 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid methyl ester|721970-35-0|C22H26FN3O4|415.46| Moxifloxacin Hydrochloride| 1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride|186826-86-8|C21H25ClFN3O4|437.89|

    Water Content (Karl Fischer)





    (HPLC, As Is): ≥98.0%



    Ackermann G et al (2000)  comparative activity of Moxifloxacin in vitro against obligately anaerobic bacteria.  Eur. J. Clin. Microbiol. Infect. Dis. 19(3):228-232 

    Araujo FG, Slifer TL and Remington JS (2002)  Effect of moxifloxacin on secretion of cytokines by human monocytes stimulated with lipopolysaccharide. Clin. Microbiol. Infect. 8(1):26-30

    Dalhoff A (2001)  Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118. Clin Infect Dis 32 Suppl 1:S16-22  PMID 11249824

    Dalhoff A, Krasemann C, Wegener S, Tillotson G (2001)  Penicillin-resistant Streptococcus pneumoniae: review of moxifloxacin activity. Clin Infect Dis. 32 Suppl 1:S22-9  PMID 11249825

    Kernt M et al (2009)  Intracameral moxifloxacin: In vitro safety on human ocular cells. Cornia 28(5):553-561

    Wolfson JS  and Hooper DC (1985)  The Fluoroquinolones: Structures, mechanisms of action and resistance, and spectra of activity in vitro. 28:581-86

Other Items In This Category